Home ProductsRemdesivir Powder

Cas 55094-52-5 Remdesivir Powder / Pharmaceutical Intermediate C26H26O6

Cas 55094-52-5 Remdesivir Powder / Pharmaceutical Intermediate C26H26O6

    • Cas 55094-52-5 Remdesivir Powder / Pharmaceutical Intermediate C26H26O6
    • Cas 55094-52-5 Remdesivir Powder / Pharmaceutical Intermediate C26H26O6
  • Cas 55094-52-5 Remdesivir Powder / Pharmaceutical Intermediate C26H26O6

    Product Details:

    Place of Origin: China
    Brand Name: Leji
    Model Number: Remedesivir Intermediate

    Payment & Shipping Terms:

    Minimum Order Quantity: Negotiation
    Price: Negotiation
    Packaging Details: Aluminum Foil Bag, barrel, or drum.
    Delivery Time: 7-15 working days
    Payment Terms: T/T, western union, moneygram
    Supply Ability: 5 - 25 metric ton per month
    Contact Now
    Detailed Product Description
    Other Names: Remedesivir Intermediate Appearance: Pharmaceutical Intermediate
    Application: Virus Treatment Cas No.: 55094-52-5
    Mf: C26H26O6 Molecular Weight: 418.48200
    Type: Amino Acid Density: 1.21±0.1 G/cm3(Predicted)
    Melting Point: 47 - 50 °C Boiling Point: 576.8±50.0 °C(Predicted)
    LogP: 4.29940 PSA: 53.990
    Package: 25kg/carton Drum Shelf Life: 24 Months
    High Light:

    pharmaceutiacal remdesivir


    remdesivir intermediate

    Cas 55094-52-5 Remdesivir Intermediates cOVID-19 Treatment Pharmaceutical Intermediate





    Product Parameters


    CAS No. 13956-29-1
    Molecular Formula C26H26O6
    Molecular Weight 418.48200
    LogP 4.29940
    PSA 53.990
    Flash point 11 °C
    Melting point 47 - 50 °C
    Boiling point 576.8±50.0 °C(Predicted)

    1.21±0.1 g/cm3(Predicted)

    Shelf life 2 Years





        Although there is no data to prove the anti-2019-ncov activity of remdesivir, the activity data displayed by remdesivir in other coronaviruses give us confidence. Remdesivir showed good activity against mers and SARS virus in vitro and in the  animal model. These viruses are similar to 2019-ncov in structure. At present, we have some clinical data about emergency treatment of Ebola patients with remdesivir for reference.
       Remdesivir, a nucleoside analogue, is an RNA dependent RNA polymerase (RdRp) inhibitor, which can inhibit the synthesis of viral nucleic acids. At present, the clinical research of Ebola virus infection has reached stage II. Mice infected with mers performed much better after this combination therapy, with reduced virus replication and improved lung function.
       "Remdesivr has activity for every coronavirus we tested, and I would be surprised if it has no activity for 2019 ncov," said Mark Denison, an American coronavirus expert. "It should be emphasized that although remdesivr has done well in reducing the virus level in the body, the earlier it is administered, the better."



       Remdesivir is a nucleotide analogue prodrug. In vitro experiments and animal model data showed that Remdesivir inhibited RNA dependent RNA synthetase (RdRp), including SARS coronavirus, mers coronavirus, Ebola coronavirus and many other coronaviruses. A novel coronavirus in Reed cell was found to have a median effective concentration (IC50) of 0.77 mol L-1. However, Remdesivir has not been approved for marketing in any country, and its effectiveness and safety have not been confirmed by phase III clinical trials. Only phase II clinical trials are conducted for Ebola virus.




    Q1: How long is your delivery time?


    A: Prompt shipment after receipt of order confirmation for regular products. Generally it is 1-5 days if the goods are in stock. or it is 5-15 days if the goods are not in stock, it is according to quantity.

    Q2: How much for the freight?
    A: It depends on your area, we will use DHL, FedEx and EMS bulk service, it had discount as normal express service.
    Q3: How can i release the payment to you?
    A: We can receive your payment by T/T, moneygram or Western union which is recommended.


    Contact Details
    Wuxi Leji Biological Technology Co., Ltd

    Contact Person: Max

    Send your inquiry directly to us (0 / 3000)